Bausch plus Lomb Corporation (BLCO) Actualités

Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today...

Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today...

Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and...

Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Bausch + Lomb Responds to Rumors of a Potential Sale

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the...

Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today...

Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Bausch + Lomb Announces Third-Quarter 2024 Results

Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP)1 of $212 Million;...

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today...